Cargando...

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

Gardado en:
Detalles Bibliográficos
Publicado en:Leukemia
Main Authors: Zabriskie, M S, Eide, C A, Yan, D, Vellore, N A, Pomicter, A D, Savage, S L, Druker, B J, Deininger, M W, O'Hare, T
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2016
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4873472/
https://ncbi.nlm.nih.gov/pubmed/26582647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.318
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!